Personalis Current Ratio 2018-2026 | PSNL
Personalis current ratio from 2018 to 2026. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Personalis Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2026-06-30 | $0.25B | $0.05B | 5.28 |
| 2026-03-31 | $0.26B | $0.04B | 6.61 |
| 2025-12-31 | $0.27B | $0.04B | 6.76 |
| 2025-09-30 | $0.17B | $0.04B | 4.82 |
| 2025-06-30 | $0.19B | $0.03B | 6.10 |
| 2025-03-31 | $0.21B | $0.03B | 6.91 |
| 2024-12-31 | $0.20B | $0.03B | 6.52 |
| 2024-09-30 | $0.17B | $0.04B | 4.68 |
| 2024-06-30 | $0.11B | $0.03B | 3.31 |
| 2024-03-31 | $0.12B | $0.03B | 3.84 |
| 2023-12-31 | $0.15B | $0.05B | 3.11 |
| 2023-09-30 | $0.15B | $0.03B | 4.56 |
| 2023-06-30 | $0.16B | $0.03B | 5.63 |
| 2023-03-31 | $0.18B | $0.03B | 5.35 |
| 2022-12-31 | $0.20B | $0.03B | 6.03 |
| 2022-09-30 | $0.22B | $0.03B | 6.58 |
| 2022-06-30 | $0.26B | $0.04B | 6.27 |
| 2022-03-31 | $0.29B | $0.04B | 7.38 |
| 2021-12-31 | $0.32B | $0.03B | 10.16 |
| 2021-09-30 | $0.33B | $0.03B | 12.41 |
| 2021-06-30 | $0.35B | $0.03B | 10.39 |
| 2021-03-31 | $0.37B | $0.04B | 9.66 |
| 2020-12-31 | $0.22B | $0.04B | 5.43 |
| 2020-09-30 | $0.22B | $0.04B | 6.23 |
| 2020-06-30 | $0.12B | $0.04B | 2.79 |
| 2020-03-31 | $0.14B | $0.05B | 2.60 |
| 2019-12-31 | $0.14B | $0.05B | 2.79 |
| 2019-09-30 | $0.14B | $0.05B | 2.96 |
| 2019-06-30 | $0.18B | $0.06B | 3.13 |
| 2019-03-31 | $0.00B | 0.00 | |
| 2018-12-31 | $0.00B | 0.00 | |
| 2018-09-30 | $0.00B | 0.00 | |
| 2018-06-30 | $0.00B | 0.00 | |
| 2017-12-31 | $0.00B | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.687B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |